High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten(+/-) mice

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3605-3611

  Stambolic, Vuk ^a   Tsao, Ming Sound ^b   Macpherson, David ^a   Suzuki, Akira ^c   Chapman, William B ^b   Mak, Tak W ^a  

^a Amgen Canada Inc   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER INCIDENCE; COWDEN SYNDROME; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

AGING; ANIMALS; CROSSES, GENETIC; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0034234268     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington, DC), 275: 1943-1947, 1997.
2. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H., and Tavtigian, S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet., 15; 356-362, 1997.
3. Li, D. M., and Sun, H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res., 57: 2124-2129, 1997.
4. Bostrom, J., Cobbers, J. M., Wolter, M., Tabatabai, G., Weber, R. G., Lichter, P., Collins, V. P., and Reifenberger, G. Mutation of the PTEN (MMACI) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res., 58: 29-33, 1998.
5. Liu, W., James, C. D., Frederick, L., Alderete, B. E., and Jenkins, R. B. PTEN/ MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res., 57: 5254-5257, 1997.
6. Rasheed, B. K., Stenzel, T. T., McLendon, R. E., Parsons, R., Friedman, A. H., Friedman, H. S., Bigner, D. D., and Bigner, S. H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res., 57: 4187-4190, 1997.
7. Wang, S. I., Puc. J., Li, J., Brace, J. N., Cairns, P., Sidransky, D., and Parsons, R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res., 57: 4183-4186, 1997.
8. Duerr, E. M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R., Eng, C., and von Deimling, A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 16: 2259-2264, 1998.
9. Zhou, X. P., Li, Y. J., Hoang-Xuan, K., Laurent-Puig, P., Mokhtari, K., Longy, M., Sanson, M., Delattre, J. Y., Thomas, G., and Hamelin, R. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer, 84: 150-154, 1999.
10. Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., and Sidransky, D. Frequent inactivation of PTEN/ MMAC1 in primary prostate cancer. Cancer Res., 57: 4997-5000, 1997.
11. Dahia, P. L., Marsh, D. J., Zheng, Z., Zedenius, J., Komminoth, P., Frisk, T., Wallin, G., Parsons, R., Longy, M., Larsson, C., and Eng, C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res., 57: 4710-4713, 1997.
12. Teng, D. H., Hu, R., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., Vinson, V. L., Gumpper, K. L., Ellis, L., El-Naggar, A., Frazier, M., Jasser, S., Langford, L. A., Lee, J., Mills, G. B., Pershouse, M. A., Pollack, R. E., Tornos, C., Troncoso, P., Yung, W. K., Fujii, G., Berson, A., Bookstein, R., Bolen, J. B., Tavtigian, S. V., and Steck, P. A. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res., 57: 5221-5225, 1997.
13. Risinger, J. I., Hayes, A. K., Berchuck, A., and Barrett, J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res., 57: 4736-4738, 1997.
14. Risinger, J. I., Hayes, K., Maxwell, G. L., Carney, M. E., Dodge, R. K., Barrett, J. C., and Berchuck, A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res., 4: 3005-3010, 1998.
15. Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, S. I., Li, J., Parsons, R., and Ellenson, L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res., 57: 3935-3940, 1997.
16. Marsh, D. J., Dahia, P. L., Caron, S., Kum, J. B., Frayling, I. M., Tomlinson, I. P., Hughes, K. S., Eeles, R. A., Hodgson, S. V., Murday, V. A., Houlston, R., and Eng, C. Germline PTEN mutations in Cowden syndrome-like families. J. Med. Genet., 35: 881-885, 1998.
17. Maehama, T., and Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273: 13375-13378, 1998.
18. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., and Mak, T. W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95: 29-39, 1998.
19. Davies, M. A., Koul, D., Dhesi, H., Berman, R., McDonnell, T. J., McConkey, D., Yung, W. K., and Steck, P. A. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res., 59: 2551-2556, 1999.
20. 1 growth arrest in glioma cells. Cancer Res., 58: 5002-5008, 1998.
21. Sun, H., Lesche, R., Li, D. M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., and Wu, H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA, 96: 6199-6204, 1999.
22. 1 arrest followed by cell death. Cancer Res., 59: 5808-5814, 1999.
23. Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R., and Yamada, K. M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (Washington, DC), 280: 1614-1617, 1998.
24. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C., and Parsons, R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16: 64-67, 1997.
25. Eng, C. Genetics of Cowden syndrome: through the looking glass of oncology. Int. J. Oncol., 12: 701-710, 1998.
26. Marsh, D. J., Kum, J. B., Lunetta, K. L., Bennett, M. J., Gorlin, R. J., Ahmed, S. F., Bodurtha, J., Crowe, C., Curtis, M. A., Dasouki, M., Dunn, T., Feit, H., Geraghty, M. T., Graham, J. M., Jr., Hodgson, S. V., Hunter, A., Korf, B. R., Manchester, D., Miesfeldt, S., Murday, V. A., Nathanson, K. L., Parisi, M., Pober, B., Romano, C., Tolmie, J. L., Trembath, R., Winter, R. M., Zackal, E. H., Zori, R. T., Weng, L-P., Dahia, P. L. M., and Eng, C. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum. Mol. Genet., 8: 1461-1472, 1999.
27. Marsh, D. J., Coulon, V., Lunetta, K. L., Rocca-Serra, P., Dahia, P. L., Zheng, Z., Liaw, D., Caron, S., Duboue, B., Lin, A. Y., Richardson, A. L., Bonnetblanc, J. M., Bressieux, J. M., Cabarrot-Moreau, A., Chompret, A., Demange, L., Eeles, R. A., Yahanda, A. M., Fearon, E. R., Fricker, J. P., Gorlin, R. J., Hodgson, S. V., Huson, S., Lacombe, D., Eng, C., et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet., 7: 507-515, 1998.
28. Marsh, D. J., Dahia, P. L., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R. J., and Eng, C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet., 16: 333-334, 1997.
29. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., Fukumoto, M., and Mak, T. W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol., 8: 1169-1178, 1998.
30. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., and Parsons, R. Mutation of Pten/ Mmacl in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA, 96: 1563-1568, 1999.
31. Di Cristofano, A., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K. B., and Pandolfi, P. P. Impaired Fas response and autoimmunity in Pten+/- mice. Science (Washington, DC), 285: 2122-2125, 1999.
32. Turusov, V. S. and Mohr, U. Tumors of the Mouse. Pathology of Tumors in Laboratory Animals, Ed. 2, Vol. 2, pp. 47-100. Lyon, France: IARC, 1994.
33. Dahia, P. L., Aguiar, R. C., Alberta, J., Kum, J. B., Caron, S., Sill, H., Marsh, D. J., Ritz, J., Freedman, A., Stiles, C., and Eng, C. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum. Mol. Genet., 8: 185-193, 1999.
34. Staal, S. P., and Hartley, J. W. Thymic lymphoma induction by the AKT8 murine retrovirus. J. Exp. Med., 167: 1259-1264, 1988.
35. Eng, C., and Peacocke, M. PTEN and inherited hamartoma-cancer syndromes. Nat. Genet., 19: 223, 1998.
36. Schrager, C. A., Schneider, D., Gruener, A. C., Tsou, H. C., and Peacocke, M. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum. Pathol., 29: 47-53, 1998.
37. Perren, A., Weng, L. P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., and Eng, C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol., 155: 1253-1260, 1999.
38. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59: 4291-4296, 1999.
39. Vlietstra, R. J., van Alewijk, D. C., Hermans, K. G., van Steenbrugge, G. J., and Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res., 58: 2720-2723, 1998.
40. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., and Stokoe, D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol., 8: 1195-1198, 1998.
41. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA, 89: 9267-9271, 1992.
42. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., and Testa, J. R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA, 93: 3636-3641, 1996.
43. Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., and Masciullo, V. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer, 64: 280-285, 1995.
44. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., and Roth, R. A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem., 274: 21528-21532, 1999.